CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues

CytomX Therapeutics, Inc.

Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.
Safety Review Committee convened July 14, 2025, supported continued study execution and enrollment.
FDA notified on July 18, 2025; company aware on July 11, 2025.
CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg each enrolled ~20 patients as planned.
Phase 1 data update expected by Q1 2026.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.